Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of rituximab (Roche Products) to submit evidence of the clinical and cost effectiveness of rituximab in combination with corticosteroids for treatment of an...
Auteurs principaux: | Latimer, N, Carroll, C, Wong, R, Tappenden, P, Venning, M, Luqmani, R |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
2014
|
Documents similaires
-
Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
par: Latimer, N, et autres
Publié: (2014) -
Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
par: Guerry, M, et autres
Publié: (2012) -
Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
par: Flossmann, O, et autres
Publié: (2006) -
Successful use of rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis
par: Michael A Paley, et autres
Publié: (2019-01-01) -
Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis
par: Robson, J, et autres
Publié: (2017)